NLS Pharmaceutics Files 2024 Annual Report
Ticker: NCEL · Form: 20-F · Filed: May 16, 2025 · CIK: 1783036
Sentiment: neutral
Topics: annual-report, 20-f, pharmaceuticals
TL;DR
NLS Pharma dropped its 2024 20-F, check it for the latest on their biz.
AI Summary
NLS Pharmaceutics Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, incorporated in Switzerland, is involved in the pharmaceutical preparations industry. Its principal executive offices are located in Zurich, Switzerland, and the CEO is Alexander Zwyer.
Why It Matters
This filing provides investors with a comprehensive overview of NLS Pharmaceutics' financial performance and business operations for the past fiscal year, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, NLS Pharmaceutics faces inherent risks related to drug development, regulatory approvals, and market competition, which are typically detailed in a 20-F filing.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Registrant
- December 31, 2024 (date) — Fiscal year end
- Alexander Zwyer (person) — Chief Executive Officer
- Zurich, Switzerland (location) — Principal executive offices
FAQ
What is the primary business of NLS Pharmaceutics Ltd. as indicated in the filing?
The filing indicates NLS Pharmaceutics Ltd. is in the Pharmaceutical Preparations industry, with SIC code 2834.
When is the fiscal year end for NLS Pharmaceutics Ltd.?
The fiscal year end for NLS Pharmaceutics Ltd. is December 31.
Who is the Chief Executive Officer of NLS Pharmaceutics Ltd.?
Alexander Zwyer is the Chief Executive Officer of NLS Pharmaceutics Ltd.
Where are the principal executive offices of NLS Pharmaceutics Ltd. located?
The principal executive offices are located at The Circle 6, 8058 Zurich, Switzerland.
What type of filing is this for NLS Pharmaceutics Ltd.?
This is an Annual Report on Form 20-F for the fiscal year ended December 31, 2024.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on May 16, 2025 by Alexander Zwyer regarding NLS Pharmaceutics Ltd. (NCEL).